Robert W. Hallowell

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster et al. · Arthritis & Rheumatology · 2024 · 130 citations · Full text

mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis

Robert W. Hallowell, Samuel L. Collins, John M. Craig et al. · Nature Communications · 2017 · 128 citations · Full text

2023 American College of Rheumatology (<scp>ACR</scp>)/American College of Chest Physicians (<scp>CHEST</scp>) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster et al. · Arthritis & Rheumatology · 2024 · 99 citations · Full text

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster et al. · Arthritis Care & Research · 2024 · 81 citations · Full text